Evaluation Of Beta Amyloid Ab40 And Ab42 Ratio in New Jersey

New Jersey Pricing in Context

In New Jersey, CPT code 0346U (Evaluation Of Beta Amyloid Ab40 And Ab42 Ratio) carries an average Medicare payment of $47.22 — 20% below the national benchmark of $59.35. 1 providers across the state submitted claims for this procedure in 2023, performing 568 total services. Individual payments in NJ ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in New Jersey is $650.50, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because New Jersey sits below the national Medicare average, commercial rates in the state may also run lower than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Genetic/Molecular Test procedures, the estimated commercial insurance price in New Jersey lands near $120.41, with self-pay cash prices typically around $214.30. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.